Bardoxolone methyl is under clinical development by Reata Pharmaceuticals and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bardoxolone methyl’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bardoxolone methyl overview
Bardoxolone methyl (RTA 402) is under development for the treatment of pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH), pulmonary hypertension associated with interstitial lung diseases (PH-ILD), idiopathic pulmonary arterial hypertension (I-PAH) and chronic kidney disease (chronic renal failure) caused by Alport syndrome and various forms of chronic kidney disease (CKD) including autosomal dominant polycystic kidney disease, IgA nephropathy (Berger's disease), type 1 diabetes and complications associated with COVID-19. It is administered orally in the form of a capsule. RTA 402 is a synthetic triterpenoid compound. The drug candidate is based on a proprietary technology platform known as Antioxidant Inflammation Modulators (AIMs). The drug candidate acts by targeting the mutated kelch like ECH associated protein 1 (KEAP1).
It was also under development for the treatment of focal segmental glomerulosclerosis, metastatic melanoma, pancreatic cancer, chronic kidney disease due to alport syndrome, liver diseases, solid tumors and rheumatoid arthritis.
Reata Pharmaceuticals overview
Reata Pharmaceuticals (Reata) is a clinical-stage biopharmaceutical company. It develops innovative medicines for the treatment of serious and life-threatening diseases. The company’s clinical candidates include bardoxolone methyl and omaveloxolone, which target Nrf2, a transcription factor, for restoring mitochondrial function, reducing oxidative stress, and resolving inflammation. Its products also include HSP90 modulators, RTA 901, ROR?t inhibitors, and RTA 1701. Reata is evaluating bardoxolone methyl in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), alport syndrome and other kidney diseases; and omaveloxolone in Friedreich’s ataxia. The company works in partnership with academics, biotechnology, and pharmaceutical companies to develop technologies. It has operations in the US, the UK, Ireland, Australia and Switzerland. Reata is headquartered in Plano, Texas, the US.
For a complete picture of Bardoxolone methyl’s drug-specific PTSR and LoA scores, buy the report here.